EW Stock Overview
Provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Edwards Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$74.81 |
| 52 Week High | US$96.12 |
| 52 Week Low | US$58.93 |
| Beta | 1.13 |
| 1 Month Change | 6.14% |
| 3 Month Change | 12.78% |
| 1 Year Change | -1.35% |
| 3 Year Change | -42.71% |
| 5 Year Change | -3.44% |
| Change since IPO | 5,340.73% |
Recent News & Updates
Edwards Lifesciences Corporation's (NYSE:EW) Price Is Out Of Tune With Earnings
Dec 23
Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Dec 09At US$71.27, Is Edwards Lifesciences Corporation (NYSE:EW) Worth Looking At Closely?
Nov 26Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11Recent updates
Edwards Lifesciences Corporation's (NYSE:EW) Price Is Out Of Tune With Earnings
Dec 23Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Dec 09At US$71.27, Is Edwards Lifesciences Corporation (NYSE:EW) Worth Looking At Closely?
Nov 26Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Shareholder Returns
| EW | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.2% | -1.2% | -2.7% |
| 1Y | -1.3% | 10.0% | 23.4% |
Return vs Industry: EW underperformed the US Medical Equipment industry which returned 10% over the past year.
Return vs Market: EW underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| EW volatility | |
|---|---|
| EW Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: EW has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EW's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 19,800 | Bernard Zovighian | www.edwards.com |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.
Edwards Lifesciences Corporation Fundamentals Summary
| EW fundamental statistics | |
|---|---|
| Market cap | US$44.12b |
| Earnings (TTM) | US$1.57b |
| Revenue (TTM) | US$6.31b |
28.2x
P/E Ratio7.0x
P/S RatioIs EW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EW income statement (TTM) | |
|---|---|
| Revenue | US$6.31b |
| Cost of Revenue | US$1.48b |
| Gross Profit | US$4.84b |
| Other Expenses | US$3.27b |
| Earnings | US$1.57b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.66 |
| Gross Margin | 76.60% |
| Net Profit Margin | 24.82% |
| Debt/Equity Ratio | 6.2% |
How did EW perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 00:20 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Edwards Lifesciences Corporation is covered by 74 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Francis Mainwaring | Atlantic Equities LLP |
| David Rescott | Baird |
| Ishan Majumdar | Baptista Research |